Hepatology CommuniCations, Vol. 4, no. 4, 2020
Bile Acid Diarrhea and NAFLD: Shared
Pathways for Distinct Phenotypes
Michael J. Weaver,1* Scott A. McHenry,1* Gregory S. Sayuk,1,2 C. Prakash Gyawali,1 and Nicholas O. Davidson1
Irritable bowel syndrome with diarrhea (IBS-D) and NAFLD are both common conditions that may be influenced
by shared pathways of altered bile acid (BA) signaling and homeostatic regulation. Pathophysiological links between
IBS-D and altered BA metabolism include altered signaling through the ileal enterokine and fibroblast growth factor 19 (FGF19) as well as increased circulating levels of 7α-hydroxy-4-cholesten-3-one, a metabolic intermediate that
denotes increased hepatic BA production from cholesterol. Defective production or release of FGF19 is associated with
increased BA production and BA diarrhea in some IBS-D patients. FGF19 functions as a negative regulator of hepatic cholesterol 7α-hydroxylase; therefore, reduced serum FGF19 effectively de-represses hepatic BA production in a
subset of IBS-D patients, causing BA diarrhea. In addition, FGF19 modulates hepatic metabolic homeostatic response
signaling by means of the fibroblast growth factor receptor 4/klotho beta receptor to activate cascades involved in hepatic lipogenesis, fatty acid oxidation, and insulin sensitivity. Emerging evidence of low circulating FGF19 levels in
subsets of patients with pediatric and adult NAFLD demonstrates altered enterohepatic BA homeostasis in NAFLD.
Conclusion: Here we outline how understanding of shared pathways of aberrant BA homeostatic signaling may guide
targeted therapies in some patients with IBS-D and subsets of patients with NAFLD. (Hepatology Communications
2020;4:493-503).
I
rritable bowel syndrome (IBS), defined clinically
by chronic abdominal pain and altered bowel habits without an identifiable organic cause, affects
up to 15% of the adult population.(1) Although visceral hypersensitivity(2) and abnormal gut motility(3)
are core abnormalities, several other factors participate
in symptom generation in IBS, including genetic susceptibility,(4) alterations in fecal microbiota,(5) bacterial overgrowth,(6) intestinal inflammation,(7) dietary
intolerance (including carbohydrate malabsorption,)(8)
and gluten sensitivity.(9) In addition, in a subset of
patients with irritable bowel syndrome with diarrhea
(IBS-D), the pathophysiology may include excess
delivery of bile acids (BAs) into the colonic lumen,
resulting in net fluid and electrolyte secretion.(10,11)
BA diarrhea (BAD) is a common contributing factor
in as many as 25% to 50% of patients with IBS-D or
functional diarrhea.(12,13) BAD has an estimated prevalence of 1% among the adult population, hence afflicting
as many as 10 million people in Western societies.(12)
There are at least three distinct categories of BAD: (1)
type 1 BAD, a consequence of anatomical disruption
from ileal resection, radiation injury, or disease (e.g.,
Crohn’s disease), ultimately resulting in BA malabsorption (BAM); (2) type 2 BAD, a heterogeneous condition associated with increased BA production that can
Abbreviations: ASBT, apical sodium-dependent bile salt transporter; BA, bile acid; BAD, bile acid diarrhea; BAM, bile acid malabsorption;
C4, 7α-hydroxy-4-cholesten-3-one; CA, cholic acid; CDCA, chenodeoxycholic acid; CYP7A1, cholesterol 7α-hydroxylase; FGF, fibroblast growth
factor; FGFR4, fibroblast growth factor receptor 4; FXR, farnesoid X receptor; IBS, irritable bowel syndrome; IBS-D, irritable bowel syndrome
with diarrhea; KLB, klotho beta; KO, knockout; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic
steatohepatitis; OCA, obeticholic acid; OST, organic solute transporter; RXR, retinoid X receptor; 75SeHCAT, selenium-75-labeled homocholic acid
conjugated taurine; SHP, small heterodimer partner; Slc10a2, solute carrier family 10 member 2; UDCA, ursodeoxycholic acid.
Received October 31, 2019; accepted January 13, 2020.
*These authors contributed equally to this work.
Financial Support: This study was supported by the National Institutes of Health (HL-38180, DK-119437, and DK-112378) and the Digestive
Disease Research Core Center (P30 DK-52574 to N.O.D. and T32 DK-07130 to M.J.W., S.A.M., and N.O.D.).
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver
Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are
made.
493
WeaVeR et al.
Hepatology CommuniCations, april 2020
Fig. 1. (A) The prevalence of obesity in the U.S. population is estimated at approximately 40% compared with NAFLD at 30% and
IBS-D at 10%-15%. The estimated overlap between obesity and NAFLD is 75%-90%, between obesity and IBS-D is 10%-20%, and
between IBS-D and NAFLD is 10%-20%. There is a presumed overlap of obesity, NAFLD, and IBS-D; these proportions are yet to be
determined. (B) Data support that 25%-50% of patients diagnosed with IBS-D have BAD, and 10%-20% will have concurrent NAFLD.
There is a presumed overlap of IBS-D, NAFLD, and BAD; these proportions are yet to be determined.
overlap with IBS-D or functional diarrhea; and (3) type
3 BAD, consisting of miscellaneous organic gastrointestinal disorders that affect BA absorption, including
celiac disease, chronic pancreatitis, small intestinal bacterial overgrowth, and lymphocytic/microscopic colitis.(10,14) Type 2 BAD has defined pathophysiology in
which increased luminal colonic BA accelerates colonic
transit and causes loose stools.(11) Important pathophysiological consequences of type 2 BAD include increased
intestinal permeability, increased fecal fat, and, in a subgroup with high total fecal BA output (>2,300 mM in
48 hours), increased representation of the primary BA,
chenodeoxycholic acid (CDCA).(15) Reflecting these
pathophysiological associations, IBS patients with type
2 BAD usually respond to BA sequestrants, implicating
aberrant BA regulation as an important target in the
pathogenesis of a subset of IBS-D that may be amenable to pharmacologic intervention.(16)
The burgeoning global epidemic of obesity has
focused attention on its associated comorbidities, including NAFLD. There is considerable overlap in population prevalence of obesity and NAFLD (Fig. 1A).(17)
However, emerging studies also point to an overlap
between obesity and IBS-D (Fig. 1A).(18) Other studies
have demonstrated a higher prevalence of NAFLD in
patients with BAD,(19) and yet other work has shown
increased diarrhea symptoms in a subset of patients
with NAFLD (Fig. 1).(20) These factors, known pathophysiological links between altered BA metabolism
and diarrhea, coupled with evidence linking aberrant
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep4.1485
Potential conflict of interest: Dr. Gyawali consults for Medtronic, Diversatek, Ironwood, Isothrive, and Quintiles.
aRtiCle inFoRmation:
From the 1 Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO; 2 U.S. Department of Veterans
Affairs, VA St. Louis Health Care System, John Cochran Division, St. Louis, MO.
aDDRess CoRResponDenCe anD RepRint ReQuests to:
Nicholas O. Davidson, M.D., D.Sc.
Division of Gastroenterology
Washington University School of Medicine
494
660 S Euclid Ave, St. Louis, MO 63110
E-mail: nod@wustl.edu
Tel.: +1-314-362-2027
Hepatology CommuniCations, Vol. 4, no. 4, 2020
BA signaling to impaired metabolic homeostasis,(21)
have heightened awareness of shared pathophysiologic
pathways in subsets of patients with both BAD and
NAFLD. This association is reinforced by emerging
data demonstrating the overlap of phenotypes linking
obesity, NAFLD, IBS-D, and BAD (Fig. 1B) and by
the findings with therapeutic agents targeting BAM in
both BAD and NAFLD. Here we review aspects of BA
pathophysiology and homeostatic signaling, with special
emphasis on how disturbances in select signaling pathways may contribute to clinical manifestations, linking
obesity phenotypes and BAD-related disorders.
Physiology of BA
Metabolism and
Derangements in BAD
Primary BAs (cholic acid [CA] and CDCA) are
produced in the hepatocyte from enzymatic modification of cholesterol in a multistep process for which
the rate-limiting step is cholesterol 7α-hydroxylase
(CYP7A1) activity (Fig. 2). (22,23) The classical pathway,
occurring in the liver, is the dominant route for BA production in humans, as shown by the greater than 90%
reduction in BA production in rare subjects with mutational CYP7A1 deletion.(24) Affected individuals exhibit
hypercholesterolemia and decreased (but not zero)
hepatic CYP7A1 activity and increased 27α-hydroxylase
(CYP27A1) activity.(24) Those findings are reflected in
the increased proportion of CDCA + lithocholic acid
(LCA) (versus CA + deoxycholic acid [DCA]) found in
CYP7A1 mutant patient stool samples, again suggesting
that BA synthesis in those patients proceeds through
the alternate pathway. The distinction between classical
and alternate pathways of BA synthesis is also important in understanding the utility for intermediates in BA
production as surrogate markers of CYP7A1 activity.
Cholesterol catabolism through the classical (CYP7A1)
pathway generates 7α-hydroxycholesterol and subsequently a stable steroid intermediate, 7α-hydroxy-4cholesten-3-one (C4), the serum levels of which are a
useful surrogate for CYP7A1 activity (Fig. 2).(25) The
alternate or acidic BA synthesis pathway, which is regulated by CYP27A1 activity, generates oxysterol intermediates, which undergo steroid side chain cleavage to
produce cholanoic acids and, ultimately, CDCA.(22,23)
WeaVeR et al.
Primary BAs undergo conjugation by cytosolic and
peroxisomal BA transferases to glycine and taurine
(in an approximately 70:30 ratio) and thereafter are
exported across the canalicular membrane through
bile salt export pump/adenosine triphosphate binding
cassette subfamily B member 11 (Abcb11) (Fig. 2) and
stored in the gallbladder, along with phospholipids
and cholesterol.(26) Following a meal, gallbladder contraction is induced by cholecystokinin secretion from
duodenal l cells,(26) promoting lipid emulsification, lipolysis, and dietary fat digestion. Active BA absorption
occurs in the terminal ileum through the apical sodiumdependent bile salt transporter (ASBT), solute carrier
family 10 member 2 (Slc10a2) (Fig. 2). Within the
ileal enterocyte, BAs bind the farnesoid X receptor
(FXR),(26) which then promotes heterodimerization
with the retinoid X receptor (RXR), activating the
FXR/RXR complex. Furthermore, BAs that do not
bind to the FXR and escape first-pass metabolism
by the liver exert peripheral effects on adipose and
muscle tissue, signaling through Takeda G protein–
coupled receptor 5, to promote energy expenditure.(27)
Activation of this FXR/RXR heteromeric complex
(Fig. 2) in turn transcriptionally up-regulates expression
of both the transcriptional co-repressor small heterodimer partner (SHP) (to down-regulate Slc10a2) and
the ileal enterokine FGF15/19 (FGF15 is the murine
ortholog). FXR/RXR activation also transcriptionally up-regulates the expression of the basolateral ileal
enterocyte BA exporter organic solute transporter (Ost)
α/β, which promotes secretion of BA into the portal
vein for recirculation to the liver (Fig. 2). Ileal BAs
are transported by the ileal BA-binding protein and
secreted into the portal vein through Ostα/β (as previously) and subsequently transported into the hepatocyte
by the hepatic sodium-taurocholate co-transporting
polypeptide (NTCP), Slc10a1 (Fig. 2).(28)
Transcriptional up-regulation of ileal FGF15/19
expression is accompanied by secretion of the mature
FGF15/19 peptide into the portal vein in a process
regulated by a presumed chaperone, Diet1, a protein expressed in enterocytes.(29) Following binding
of FGF15/19 to its cognate hepatic receptor (fibroblast growth factor receptor 4 [FGFR4]/klotho
beta [KLB]), hepatic BA synthesis is then downregulated by transcriptional activation of the repressor SHP, which decreases CYP7A1 expression and
activity(26,29) and decreases primary BA production
(Fig. 2). Additional regulation of BA homeostasis
495
WeaVeR et al.
Hepatology CommuniCations, april 2020
Fig. 2. BAs are synthesized in the hepatocyte from free cholesterol by CYP7A1, generating C4 as an intermediate and surrogate of BA
synthesis and exported through bile salt export pump into the biliary canaliculus. In response to a meal, BAs are secreted into the duodenum
to aid in emulsification and absorption of dietary lipids. BAs are then reabsorbed in the terminal ileum by crossing the apical border of
ileocytes through the ASBT and then the basolateral border through Ostα/β before entering the portal circulation. Following arrival to the
hepatocyte, most BAs are taken up through NTCP and promote feedback inhibition of BA synthesis through FXR/RXR. BAs that escape
first-pass uptake by the hepatocyte will have peripheral effects on adipose and muscle tissue through Takeda G protein–coupled receptor
5, and promote energy expenditure through thyroxine and triiodothyronine. In healthy individuals, 5% of BAs do not get reabsorbed from
the ileum and therefore promote luminal chloride secretion, including through the cystic fibrosis transmembrane regulator and subsequent
osmotic force for fluid secretion in the colon. In BAD, reduced ileal secretion of FGF19 constrains negative feedback of hepatic BA synthesis,
resulting in increased hepatic BA secretion, increased delivery of BA to the colon, and subsequent diarrhea. C4, an intermediate of hepatic BA
synthesis from cholesterol and a surrogate of Cyp7a1 activity, is notably elevated in BAD and has been shown to be a reliable biomarker. In
the process of passing through the ileocyte as part of this enterohepatic circulation, BAs also activate FXR through BA-mediated liganding.
FXR/RXR activation in the ileocyte up-regulates SHP, FGF19, and Ostα/β. FGF19 is released into the portal vein and, following arrival to
the hepatocyte, FGF19 binds to FGFR4/KLB. This signal also provides negative feedback of BA biosynthesis in the liver by promoting SHP
and subsequent decreased CYP7A1 expression. Furthermore, FGF19 signaling through FGFR4/KLB has metabolic effects, which include
increased hepatic fatty acid oxidation, decreased fatty acid synthase and lipid biosynthesis, and increased insulin sensitization. Abbreviations:
CFTR, cystic fibrosis transmembrane regulator; ERK2, extracellular signal–related kinase 2; IBABP, ileal BA-binding protein; MAPK,
mitogen-activated protein kinase; and T3, triiodothyronine; T4, thyroxine; TGR5, Takeda G protein–coupled receptor 5.
occurs by recycling of BA through the portal vein and
hepatocyte reuptake. In IBS-D, BAD results from
increased colonic BA content caused by decreased ileal
496
production or secretion of FGF19 (and consequent
de-repression of BA synthesis) rather than an impairment in ileal BA absorption.(30-32) Reduced FGF19
Hepatology CommuniCations, Vol. 4, no. 4, 2020
levels impair negative feedback inhibition of hepatic
BA biosynthesis, leading to increased hepatic BA synthesis and secretion and, consequently, increased intestinal BA content. Genetic variations in the pathways
associated with BA metabolism may also play a role
in BAD in IBS-D. Specifically, a variant (rs1761844)
in KLB (encoding KLB) was associated with colonic
transit time in patients with IBS-D,(33) and other
studies showed a variant in FGFR4 (rs1966265) was
associated with fecal BA content in these patients.(34)
Other work has shown that, in addition to increased
total fecal BA output, patients with BAD excreted
greater than 10% fecal primary BA, again suggesting
increased BA synthesis.(35)
Ileal BA absorption and recycling is extremely efficient, with BA undergoing enterohepatic cycling at least
10 times daily and only 5% of luminal BAs reaching the
colon. In the colon, primary conjugated BAs undergo
microbial deconjugation, epimerization, and dehydroxylation into secondary Bas’ DCA, ursodeoxycholic acid
(UDCA), and LCA, some of which are reabsorbed
and recirculated back to the liver where they undergo
uptake and reconjugation and secretion along with the
primary BA.(22) Colonic BAs influence fluid secretion
by increasing cellular calcium and adenosine cyclic adenosine monophosphate, which in turn up-regulates epithelial chloride/bicarbonate secretion, thereby creating
an active mechanism for fluid and electrolyte secretion
and, consequently, diarrhea (Fig. 2).(36)
Biomarker Development and
Utility in Clinical Evaluation
of BAD
Because BAD is a common condition and reflects
increased fecal BA excretion, considerable efforts have
been directed at the identification of clinical biomarkers to categorize subsets of BAD.(37) The gold standard test for BAD in the United Kingdom, Canada,
and other European countries is the selenium-75labeled homocholic acid (75SeHCAT) retention test,
with BAD defined by less than 10% retention and
severe disease characterized by less than 5% retention.(12) 75SeHCAT is a modified BA that mirrors
the enterohepatic circulation of taurocholic acid.(38)
75
SeHCAT testing requires oral administration of a
WeaVeR et al.
radiolabeled synthetic BA followed by gamma camera measurement of retention at baseline and 7 days
after administration.(39) Because 75SeHCAT testing
is not available in the United States, 48-hour fecal
BA excretion is the gold standard test. Fecal BA testing measures the total mass of BA excreted per day
as a measure of increased BA production and has a
diagnostic yield for BAD of 25.5% in functional diarrhea or IBS-D.(14) A challenge of the 48-hour stool
collection is a required adherence to a high dietary
fat intake (100 g per day) for 4 days. A recent retrospective study of patients with IBS-D found that
fecal BA excretion of less than 10% primary BAs had
a 90% specificity to detect increased fecal weight and
rapid colonic transit (both surrogate clinical markers
of BAD) and that 45% of patients with chronic diarrhea exhibited elevated fecal primary BA abundance
(>10%).(35) These observations together suggest that
measuring primary fecal BA in a single stool sample
may be a useful and less cumbersome alternative to a
48-hour stool collection for identifying BAD.(35)
Another approach for diagnosing BAD is to measure fasting serum C4, a surrogate for Cyp7a1 activity and a key intermediate in BA production.(25)
Increased serum levels of C4 signify and correlate
with BA overproduction,(40,41) and this approach has
been validated to diagnose BAD when compared
with 75SeHCAT testing(42) and shown to be a reliable
screening biomarker for BAD in patients with IBSD.(13) In addition, serum C4 levels were increased
with BAD in patients with Crohn’s disease, suggesting
that C4 may be a useful biomarker to screen for other
diarrheal conditions resulting from BAM.(43) Fasting
serum FGF19 levels have also been evaluated as a
potential biomarker for BAD,(34,39) with levels less
than 61.7 pg/mL exhibiting 83% sensitivity and 78%
specificity to diagnose BAD when compared with the
48-hour BA excretion, and those specificity and sensitivity values were superior to fasting C4 levels.(39)
One caveat is that serum FGF19 concentrations rise
after meals once secreted BAs reach the terminal
ileum.(44,45) Because of the pathogenic role of defective ileal FGF19 production in BAD, the proposal
emerged that synthetic FXR agonists may have therapeutic benefit in patients with BAD by up-regulating
expression of FGF19. Indeed, this expectation was
confirmed in a small trial of the potent FXR agonist,
obeticholic acid (OCA), in which improved diarrheal
symptoms and stool form were observed in BAD.(46)
497
WeaVeR et al.
Because of increased awareness of different pathophysiological mechanisms underlying IBS-D, testing
to confirm the diagnosis of BAD has been recommended over empiric BA sequestrant therapy. The
Canadian Association of Gastroenterology clinical
practice guidelines recommend confirmatory testing with 75SeHCAT or C4 over initiating empiric
BA sequestrant therapy.(47) Individuals with a definitive diagnosis of BAD have been shown to have a
response rate of over 70% to BA sequestrant therapy,
as opposed to those with negative testing for BAD
with only 25% response to therapy.(48) Furthermore,
confirmatory testing for BAD is likely cost-effective
and reduces the need for excessive diagnostic evaluation in this subset of patients.(49)
Clinical Trials of Agents
Modifying BA Metabolism
in BAD and IBS
Cholestyramine is a BA sequestrant that reduces
diarrhea in all types of BAD. In several case series, 71%
to 93% of patients responded to cholestyramine.(50-52)
In IBS-D, as many as 96% have been reported to
respond to empirical cholestyramine therapy, with
a dose response based on severity of BAM (better
response with more severe BAM).(12) Colestipol is
an alternative BA sequestrant that has been studied
in the management of BAD,(11) and colesevelam, yet
another sequestrant, improved diarrhea in 83% of
patients with BAD,(53) with a trend toward slowing of
24-hour colonic transit time.(54)
As previously mentioned, OCA is a potent synthetic FXR agonist that has been studied in limited
patients with BAD. This agent improved clinical
symptoms, with a reduction in weekly number of
stools and mean stool form in patients with primary
BAD and patients with secondary BAD with short
ileal resections (< 45 cm). However, no improvement
in symptoms was observed in patients with idiopathic
chronic diarrhea in the absence of BAD.(55)
An inhibitor of ileal BA transport, elobixibat,
has also been studied in constipation-predominant
disorders and is a locally acting inhibitor of ASBT.
Blockade of ileal BA transport leads to increased BA
concentration in the right colon and secretory and
498
Hepatology CommuniCations, april 2020
motor effects that benefit constipation. A secondary
effect is increased serum C4, which correlates with
colonic transit and stool form.(56)
Altered BA and FGF19
Signaling in Hepatic
Triglyceride Metabolism and
NAFLD
An important physiologic role of FGF19 is suggested by the predictable postprandial increase in
circulating levels specific to dietary fat content,(57)
implying a role as an enterokine for integrating
homeostatic metabolic regulation in addition to regulating BA synthesis.
FGF19 signaling is restricted to the liver under
physiologic (endocrine) concentrations through
interactions between its receptor, the tyrosine kinase
FGFR4, and its co-receptor, KLB (Fig. 2).(58,59) As
noted, rare genetic variants of KLB, which affect the
stability of FGFR4, are associated with IBS-D(33)
and pediatric NAFLD.(60) Although these genetic
associations have yet to be linked with alterations in
FGF19 levels, one would predict (in the event that
FGF19 is actually taken up by hepatocytes) that
defects in FGFR4/KLB should result in increased
serum FGF19 levels (theoretically reflecting defective
hepatic uptake). However, this prediction is at odds
with findings from pediatric patients with NAFLD
and advanced fibrosis in which hepatic messenger
RNA expression of KLB directly correlated with
serum FGF19 concentration.(60) In addition, portal
vein and peripheral arterial and venous FGF19 concentrations were comparable in subjects undergoing
liver surgery, making it unlikely that the liver participates in clearance of FGF19.(61) Among the pertinent
phosphorylation targets of FGFR4 are the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin. However, the presence of the KLB co-receptor
shifts signaling toward the mitogen-activated protein
kinase/extracellular signal–related kinase signaling
pathway for energy use.(62) As a result, hepatic FGF19
signaling through FGFR4 increases fatty acid oxidation, decreases lipid biosynthesis (decreasing fatty acid
synthase and stearoyl-coenzyme A desaturase),(63) and
Hepatology CommuniCations, Vol. 4, no. 4, 2020
increases insulin sensitization.(64,65) These observations reinforce the premise that FGF19 deficiency is
associated with abnormal hepatic lipid metabolism.
The related hypothesis that FGF19 deficiency is associated with NAFLD in humans is supported by studies showing either lower fasting levels of FGF19 or
lower postprandial FGF19 integrated areas under the
curve.(66-69) Furthermore, this association was confirmed in a pediatric population, in whom an inverse
association was observed between serum FGF19 levels and histologic severity of NAFLD (Table 1).(60,70)
This inverse correlation between circulating
FGF19 and NAFLD in humans remains even after
adjusting for potentially relevant clinical confounders, such as body mass index, age, and gender.(60)
The hypothesis that FGF19 deficiency leads to
worsening hepatic steatosis is further supported by
a randomized trial with an FXR antagonist, UDCA,
in morbidly obese patients undergoing Roux-en-Y
gastric bypass surgery.(71) Obese patients pretreated
for 3 weeks with UDCA exhibited lower serum
concentrations of FGF19 and increased severity of
hepatic steatosis, as detected on an intraoperative
liver biopsy.
In summary, human data support a correlation
between low serum FGF19 levels and hepatic steatosis. The most biologically plausible explanation of
this relationship is that FGF19 deficiency precedes
the development of steatosis, because this deficiency
WeaVeR et al.
decreases hepatic triglyceride oxidation while simultaneously increasing de novo lipogenesis. Still, the reversal
of causality (i.e., hepatic steatosis leads to low FGF19)
remains a possibility; however, this is at odds with
studies that have shown markedly elevated FGF19
levels in patients with alternative etiologies of liver
disease, such as alcoholic hepatitis and cholestasis.(72)
Role of FGF15 in Mouse
Models of NAFLD
The literature evaluating FGF15 in mice models of NAFLD illustrate the strong interaction
among this FGF signaling pathway, genetics,
dietary composition, and mitochondrial metabolism (Table 2). Many of the findings are consistent
with the expected roles described previously, such
as transgenic FGF19 expression protecting against
hepatic steatosis(73) and ileal FXR deletion (which
reduces FGF15 production), worsening hepatic
steatosis from high-fat feeding.(74) On the other
hand, although FGF15 knockout (KO) mice exhibit
hepatic steatosis and insulin resistance, the severity
of steatohepatitis was no different.(75) Furthermore,
hepatic steatosis induced by tetracycline administration was actually prevented by the antagonism of
FGF15 signaling by using either Fgfr4 KO mice(63)
taBle 1. stuDies oF FgF19 in patients WitH naFlD
First Author (Reference)
Eren(68)
NAFLD Diagnosis
Biopsy
N (Cases)
91 (adults)
Fasting FGF19 (Median pg/mL)
130 (NAFLD)
P Value
<0.001
210 (controls)
Mouzaki(69)
Biopsy
21 (adults)
57 (NASH)
0.114
101 (SS)
116 (controls)
Schreuder(66)
Ultrasound
20 (adults)
180 (NAFLD)
0.94
260 (controls)
Friedrich(67)
Ultrasound
26 (adults)
116 (obese NAFLD)
0.01
128 (overweight)
178 (controls)
Nobili(70)
Biopsy
33 (pediatric)
55 (NASH)
<0.01
100 (SS)
175 (controls)
Alisi(60)
Biopsy
84 (pediatric)
41 (NASH)
<0.001
80 (SS)
201 (controls)
Abbreviation: SS, simple steatosis.
499
WeaVeR et al.
Hepatology CommuniCations, april 2020
taBle 2. stuDies oF FgF15/19 in mouse moDels oF naFlD
First Author (Reference)
Diet
Intervention
Findings Related to FGF19 Axis
Schumacher(75)
High fat vs. chow
FGF15 KO
There was no difference in grade of steatosis
Schmitt(74)
1% cholesterol vs. chow
Selective (ileal or hepatic) FXR KO
1% cholesterol diet (but not chow) in ileal FXR-KO
mice predisposes to hepatic steatosis
Chen(76)
Tetracycline
FGFR4 extracellular domain
FGFR4 antagonism prevents microvesicular hepatic
steatosis
Fu(73)
High fat vs. chow in ob/ob mice
Transgenic expression FGF19
Increased serum FGF19 protects against NAFLD
Huang(63)
High fat vs. chow
FGFR4 KO
FGFR4 KO mice fed high-fat diet were protected
against hepatic steatosis despite increased
dyslipidemia
Abbreviation: ob/ob, obese.
or therapeutic administration of the FGFR4 extracellular domain.(76) The role of extracellular FGFR4
in the prevention of tetracycline-induced hepatic
steatosis is particularly intriguing, because this
model induces hepatic steatosis through mitochondrial toxicity.(77) An interesting potential translational application to consider would be other causes
of microvesicular steatosis, such as Reye syndrome
or acute fatty liver of pregnancy; however, this speculation will require formal experimental validation.
Further mouse studies have highlighted alternative
pathways for FGF19 signaling in metabolic regulation by demonstrating that liver-specific signaling
is not required but rather that neuronal signaling mediates long-term metabolic effects on body
weight and glycemic control.(78)
Clinical Trials of Agents
Modifying Signaling
Through the FGF19 Axis
in NAFLD
The clinical use of recombinant FGF19 was initially perceived to be limited, given concerns with
potential hepatocarcinogenicity caused by FGFR4/
KLB receptor signaling through the signal transducer
and activator of transcription 3 (STAT3) pathway.(79)
However, NGM282, a bioengineered mutant variant of FGF19, does not signal through STAT3 and
has been demonstrated to be efficacious in reversing
steatosis, inflammation and fibrosis, and is protective
against hepatocellular cancer in a mouse model fed a
500
high-fat/high-fructose diet.(80) The phase 2 human
study using parenteral injection of NGM282 successfully met its primary endpoint of a less than 5% loss
in liver fat as measured by magnetic resonance proton
density fat fraction in 74% and 78% of those treated
with 3 mg and 6 mg, respectively (compared with only
9% in the placebo).(81) These observed changes were
associated with significant decreases in plasma C4 levels, suggesting that the mechanism of action involves
altered BA synthesis. NGM282 treatment also led to
increased serum low-density lipoprotein (LDL) cholesterol, primarily in large LDL particles.(81)
Similarly, the potent FXR ligand, OCA, markedly
increases FGF19 secretion.(82)
Both the FXR Ligand OCA in Nonalcoholic
Steatohepatitis Treatment Trial (FLINT), a phase
2 study, and Randomized Global Phase 3 Study to
Evaluate the Impact on NASH with Fibrosis of
Obeticholic Acid Treatment (REGENERATE), a
phase 3 study, met their primary endpoints by demonstrating both a statistically significant improvement in
the NAFLD activity score on liver biopsy without
worsening hepatic fibrosis (20% in placebo, 50% in
the 25-mg group) and fibrosis improvement without
worsening nonalcoholic steatohepatitis (NASH) (12%
in placebo, 18% in the 10-mg group and 23% in the
25-mg group), respectively.(83,84) The most common
adverse effects were pruritus and increased serum
LDL cholesterol, although there were no differences
in cardiovascular event rates. Secondary analysis of the
clinical parameters from the FLINT indicated significant interactions between weight loss and improvement in the NAFLD activity score and showed that
patients who lost weight on OCA demonstrated
increased LDL cholesterol and decreased high-density
Hepatology CommuniCations, Vol. 4, no. 4, 2020
taBle 3. oVeRlapping assoCiations oF iBs-D,
BaD, anD naFlD
IBS-D
BAD
NAFLD
FGF19 concentration
↓
↓
↓
C4 concentration
↑
↑
↑
48-hour fecal bile acids
±
↑
NS
Associated variant FGFR4/KLB
+
+
+
Response to FXR agonists
+
+
+
Obesity as risk factor
+
+
+
Abbreviations: ↑, increased concentration relative to controls; ±,
equivocal levels compared with controls; +, known association; NS,
not studied.
lipoprotein cholesterol levels.(85) These findings highlight the complexity of BA signaling, because hepatic
FXR activation with OCA would be expected to
decrease BA synthesis and in turn decrease cholesterol disposal (favoring LDL accumulation) while
also decreasing hepatic triglyceride-rich lipoprotein
production.(86) It is clear that the signaling pathways involved in weight loss with OCA treatment
are complex and remain incompletely understood;
however, these promising results have opened the
pipeline for other FXR agonists in the treatment for
NAFLD.(87,88)
In conclusion, the pathogenesis of BAD and
NAFLD appear to share overlapping mechanisms
and pathways (Table 3). Through a cognate FGFR4/
KLB receptor in the liver, FGF19 activity not only
regulates BA homeostasis but also plays a key role
in lipid metabolism and insulin sensitivity. Thus, low
serum levels of FGF19 have been implicated in the
pathogenesis of BAD in IBS-D as well as NAFLD,
and consequently, treatment paradigms that influence FGF19 homeostasis have shown benefit in small
studies in both groups of disorders. Future studies
will further elucidate the mechanisms and pathways
involved and are expected to yield novel therapeutic
targets and specific pharmacologic agents that may be
useful to treat distinctive subsets of patients with both
BAD and NAFLD.
Acknowledgment: The authors thank Anastasia E.
Zylka for the editorial assistance.
ReFeRenCes
1) Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ III.
Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991;101:927-934.
WeaVeR et al.
2) Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y,
et al. Regional cerebral activation in irritable bowel syndrome and
control subjects with painful and nonpainful rectal distention.
Gastroenterology 2000;118:842-848.
3) Simren M, Castedal M, Svedlund J, Abrahamsson H, Bjornsson
E. Abnormal propagation pattern of duodenal pressure waves in
the irritable bowel syndrome (IBS) [correction of (IBD)]. Dig Dis
Sci 2000;45:2151-2161.
4) Saito YA, Petersen GM, Locke GR III, Talley NJ. The genetics of irritable bowel syndrome. Clin Gastroenterol Hepatol
2005;3:1057-1065.
5) Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T,
Paulin L, Corander J, et al. The fecal microbiota of irritable bowel
syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33.
6) Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal
bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-3506.
7) Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S,
et al. Immune activation in patients with irritable bowel syndrome.
Gastroenterology 2007;132:913-920.
8) Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet
low in FODMAPs reduces symptoms of irritable bowel syndrome.
Gastroenterology 2014;146:67-75.e5.
9) Verdu EF, Armstrong D, Murray JA. Between celiac disease and
irritable bowel syndrome: the “no man’s land” of gluten sensitivity.
Am J Gastroenterol 2009;104:1587-1594.
10) Pattni SS, Brydon WG, Dew T, Johnston IM, Nolan JD, Srinivas
M, et al. Fibroblast growth factor 19 in patients with bile acid
diarrhoea: a prospective comparison of FGF19 serum assay and
SeHCAT retention. Aliment Pharmacol Ther 2013;38:967-976.
11) Bajor A, Tornblom H, Rudling M, Ung KA, Simren M. Increased
colonic bile acid exposure: a relevant factor for symptoms and
treatment in IBS. Gut 2015;64:84-92.
12) Wedlake L, A’Hern R, Russell D, Thomas K, Walters JR,
Andreyev HJ. Systematic review: the prevalence of idiopathic bile
acid malabsorption as diagnosed by SeHCAT scanning in patients
with diarrhoea-predominant irritable bowel syndrome. Aliment
Pharmacol Ther 2009;30:707-717.
13) Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for
diagnosis of bile acid malabsorption in clinical practice. Clin
Gastroenterol Hepatol 2013;11:1232-1239.
14) Valentin N, Camilleri M, Altayar O, Vijayvargiya P, Acosta A,
Nelson AD, et al. Biomarkers for bile acid diarrhoea in functional
bowel disorder with diarrhoea: a systematic review and metaanalysis. Gut 2016;65:1951-1959.
15) Camilleri M, Busciglio I, Acosta A, Shin A, Carlson P, Burton
D, et al. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol
2014;109:1621-1630.
16) Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and
therapy. Gut Liv 2015;9:332-339.
17) Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher
JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers
2015;1:15080.
18) Pickett-Blakely O. Obesity and irritable bowel syndrome: a comprehensive review. Gastroenterol Hepatol (N Y) 2014;10:411-416.
19) Appleby RN, Nolan JD, Johnston IM, Pattni SS, Fox J, Walters
JR. Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis. BMJ Open
Gastroenterol 2017;4:e000178.
20) Appleby RN, Moghul I, Khan S, Yee M, Manousou P, Neal TD,
et al. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: a prospective observational
study. PLoS ONE 2019;14:e0211348.
501
WeaVeR et al.
21) de Boer JF, Bloks VW, Verkade E, Heiner-Fokkema MR,
Kuipers F. New insights in the multiple roles of bile acids and
their signaling pathways in metabolic control. Curr Opin Lipidol
2018;29:194-202.
22) Chiang JY. Bile acid metabolism and signaling. Compr Physiol
2013;3:1191-1212.
23) Bjorkhem I, Araya Z, Rudling M, Angelin B, Einarsson C,
Wikvall K. Differences in the regulation of the classical and the
alternative pathway for bile acid synthesis in human liver: no
coordinate regulation of CYP7A1 and CYP27A1. J Biol Chem
2002;277:26804-26807.
24) Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson
SK, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1)
deficiency has a hypercholesterolemic phenotype. J Clin Invest
2002;110:109-117.
25) Pattni SS, Brydon WG, Dew T, Walters JR. Fibroblast growth factor 19 and 7alpha-hydroxy-4-cholesten-3-one in the diagnosis of
patients with possible bile acid diarrhea. Clin Transl Gastroenterol
2012;3:e18.
26) Keely SJ, Walters JR. The farnesoid X receptor: good for BAD.
Cell Mol Gastroenterol Hepatol 2016;2:725-732.
27) Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The
bile acid membrane receptor TGR5: a valuable metabolic target.
Dig Dis 2011;29:37-44.
28) Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res
2009;50:2340-2357.
29) Lee JM, Ong JR, Vergnes L, de Aguiar Vallim TQ, Nolan J,
Cantor RM, et al. Diet1, bile acid diarrhea, and FGF15/19:
mouse model and human genetic variants. J Lipid Res 2018;59:
429-438.
30) Johnston IM, Nolan JD, Pattni SS, Appleby RN, Zhang JH,
Kennie SL, et al. Characterizing factors associated with differences in FGF19 blood levels and synthesis in patients with primary bile acid diarrhea. Am J Gastroenterol 2016;111:423-432.
31) Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux
CW. A new mechanism for bile acid diarrhea: defective feedback
inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol
2009;7:1189-1194.
32) Hofmann AF, Mangelsdorf DJ, Kliewer SA. Chronic diarrhea due
to excessive bile acid synthesis and not defective ileal transport:
a new syndrome of defective fibroblast growth factor 19 release.
Clin Gastroenterol Hepatol 2009;7:1151-1154.
33) Wong BS, Camilleri M, Carlson PJ, Guicciardi ME, Burton D,
McKinzie S, et al. A klothobeta variant mediates protein stability
and associates with colon transit in irritable bowel syndrome with
diarrhea. Gastroenterology 2011;140:1934-1942.
34) Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I,
Bondar O, et al. Increased bile acid biosynthesis is associated
with irritable bowel syndrome with diarrhea. Clin Gastroenterol
Hepatol 2012;10:1009-1015.e3.
35) Vijayvargiya P, Camilleri M, Chedid V, Carlson P, Busciglio I,
Burton D, et al. Analysis of fecal primary bile acids detects increased stool weight and colonic transit in patients with chronic
functional diarrhea. Clin Gastroenterol Hepatol 2019;17:922-929.
e2.
36) Sun Y, Fihn BM, Sjovall H, Jodal M. Enteric neurones modulate
the colonic permeability response to luminal bile acids in rat colon
in vivo. Gut 2004;53:362-367.
37) Arasaradnam RP, Brown S, Forbes A, Fox MR, Hungin P, Kelman
L, et al. Guidelines for the investigation of chronic diarrhoea in
adults: British Society of Gastroenterology, 3rd edition. Gut
2018;67:1380-1399.
38) Jazrawi RP, Ferraris R, Bridges C, Northfield TC. Kinetics for
the synthetic bile acid 75selenohomocholic acid-taurine in humans: comparison with [14C]taurocholate. Gastroenterology
1988;95:164-169.
502
Hepatology CommuniCations, april 2020
39) Vijayvargiya P, Camilleri M, Carlson P, Lueke A, O’Neill J, Burton
D, et al. Performance characteristics of serum C4 and FGF19
measurements to exclude the diagnosis of bile acid diarrhoea in
IBS-diarrhoea and functional diarrhoea. Aliment Pharmacol Ther
2017;46:581-588.
40) Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate
fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology
2009;49:297-305.
41) Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable
bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res 2003;44:859-866.
42) Camilleri M, Shin A, Busciglio I, Carlson P, Acosta A,
Bharucha AE, et al. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil
2014;26:1677-1685.
43) Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS,
Valasek MA, et al. Serum concentrations of 7α-hydroxy-4cholesten-3-one are associated with bile acid diarrhea in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2019;17:
2722-2730.
44) Galman C, Angelin B, Rudling M. Pronounced variation in bile
acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern
Med 2011;270:580-588.
45) Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern
Med 2006;260:530-536.
46) Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol
2014;11:426-434.
47) Sadowski DC, Camilleri M, Chey WD, Leontiadis GI, Marshall
JK, Shaffer EA, et al. Canadian Association of Gastroenterology
clinical practice guideline on the management of bile acid diarrhea. Clin Gastroenterol Hepatol 2020;18:24-41.e1.
48) Walters JRF, Arasaradnam R, Andreyev HJN. Diagnosis and
management of bile acid diarrhoea: a survey of UK expert opinion
and practice. Frontline Gastroenterol 2019;0:1-6.
49) Turner JM, Pattni SS, Appleby RN, Walters JR. A positive SeHCAT test results in fewer subsequent investigations
in patients with chronic diarrhoea. Frontline Gastroenterol
2017;8:279-283.
50) Nyhlin H, Merrick MV, Eastwood MA. Bile acid malabsorption in Crohn’s disease and indications for its assessment using
SeHCAT. Gut 1994;35:90-93.
51) Ford GA, Preece JD, Davies IH, Wilkinson SP. Use of the
SeHCAT test in the investigation of diarrhoea. Postgrad Med J
1992;68:272-276.
52) Borghede MK, Schlutter JM, Agnholt JS, Christensen LA,
Gormsen LC, Dahlerup JF. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ((75)SeHCAT)
scans: causes and treatment responses to cholestyramine in
298 patients with chronic watery diarrhoea. Eur J Intern Med
2011;22:e137-e140.
53) Wedlake L, Thomas K, Lalji A, Anagnostopoulos C, Andreyev
HJ. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin Ther
2009;31:2549-2558.
54) Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton
D, Carlson P, Busciglio IA, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010;8:
159-165.
Hepatology CommuniCations, Vol. 4, no. 4, 2020
55) Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME,
Shapiro DA. The response of patients with bile acid diarrhoea
to the farnesoid X receptor agonist obeticholic acid. Aliment
Pharmacol Ther 2015;41:54-64.
56) Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H,
Zinsmeister AR. Effects of A3309, an ileal bile acid transporter
inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011;106:2154-2164.
57) Schmid A, Leszczak S, Ober I, Karrasch T, Schaffler A. Shortterm and divergent regulation of FGF-19 and FGF-21 during
oral lipid tolerance test but not oral glucose tolerance test. Exp
Clin Endocrinol Diabetes 2015;123:88-94.
58) Lin BC, Wang M, Blackmore C, Desnoyers LR. Liverspecific activities of FGF19 require klotho beta. J Biol Chem
2007;282:27277-27284.
59) Triantis V, Saeland E, Bijl N, Oude-Elferink RP, Jansen PL.
Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of
cytochrome P450 7A1. Hepatology 2010;52:656-666.
60) Alisi A, Ceccarelli S, Panera N, Prono F, Petrini S, De Stefanis C,
et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS
ONE 2013;8:e67160.
61) Johansson H, Mork LM, Li M, Sandblom AL, Bjorkhem I,
Hoijer J, et al. Circulating fibroblast growth factor 19 in portal and
systemic blood. J Clin Exp Hepatol 2018;8:162-168.
62) Luo Y, Yang C, Lu W, Xie R, Jin C, Huang P, et al. Metabolic regulator betaklotho interacts with fibroblast growth factor receptor 4
(FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
J Biol Chem 2010;285:30069-30078.
63) Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL. FGFR4
prevents hyperlipidemia and insulin resistance but underlies highfat diet induced fatty liver. Diabetes 2007;56:2501-2510.
64) Kir S, Kliewer SA, Mangelsdorf DJ. Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol 2011;76:139-144.
65) Wu X, Ge H, Baribault H, Gupte J, Weiszmann J, Lemon B, et al.
Dual actions of fibroblast growth factor 19 on lipid metabolism.
J Lipid Res 2013;54:325-332.
66) Schreuder TC, Marsman HA, Lenicek M, van Werven JR,
Nederveen AJ, Jansen PL, et al. The hepatic response to FGF19
is impaired in patients with nonalcoholic fatty liver disease and
insulin resistance. Am J Physiol Gastrointest Liver Physiol
2010;298:G440-G445.
67) Friedrich D, Marschall HU, Lammert F. Response of fibroblast growth factor 19 and bile acid synthesis after a body
weight-adjusted oral fat tolerance test in overweight and obese
NAFLD patients: a non-randomized controlled pilot trial. BMC
Gastroenterol 2018;18:76.
68) Eren F, Kurt R, Ermis F, Atug O, Imeryuz N, Yilmaz Y.
Preliminary evidence of a reduced serum level of fibroblast growth
factor 19 in patients with biopsy-proven nonalcoholic fatty liver
disease. Clin Biochem 2012;45:655-658.
69) Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM,
Zhang L, et al. Bile acids and dysbiosis in non-alcoholic fatty liver
disease. PLoS ONE 2016;11:e0151829.
70) Nobili V, Alisi A, Mosca A, Della Corte C, Veraldi S, De Vito R,
et al. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD.
Liver Int 2018;38:342-349.
71) Mueller M, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C,
et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic
effects on bile acid and lipid metabolism in morbid obesity.
J Hepatol 2015;62:1398-1404.
72) Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots
M, et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol 2018;69:396-405.
WeaVeR et al.
73) Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M,
et al. Fibroblast growth factor 19 increases metabolic rate and
reverses dietary and leptin-deficient diabetes. Endocrinology
2004;145:2594-2603.
74) Schmitt J, Kong B, Stieger B, Tschopp O, Schultze SM, Rau M,
et al. Protective effects of farnesoid X receptor (FXR) on hepatic
lipid accumulation are mediated by hepatic FXR and independent
of intestinal FGF15 signal. Liver Int 2015;35:1133-1144.
75) Schumacher JD, Kong B, Pan Y, Zhan L, Sun R, Aa J, et al. The
effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
Toxicol Appl Pharmacol 2017;330:1-8.
76) Chen Q, Jiang Y, An Y, Zhao N, Zhao Y, Yu C. Soluble FGFR4
extracellular domain inhibits FGF19-induced activation of
FGFR4 signaling and prevents nonalcoholic fatty liver disease.
Biochem Biophys Res Commun 2011;409:651-656.
77) Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis: effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997;26(Suppl. 2):43-53.
78) Lan T, Morgan DA, Rahmouni K, Sonoda J, Fu X, Burgess SC,
et al. FGF19, FGF21, and an FGFR1/beta-klotho-activating
antibody act on the nervous system to regulate body weight and
glycemia. Cell Metab 2017;26:709-718.e3.
79) Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz
GD, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160:2295-2307.
80) Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling
L. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice.
Hepatol Commun 2017;1:1024-1042.
81) Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes
AH, Arnold HL, et al. NGM282 for treatment of non-alcoholic
steatohepatitis: a multicentre, randomised, double-blind, placebocontrolled, phase 2 trial. Lancet 2018;391:1174-1185.
82) Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon
PH, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest
Liver Physiol 2013;304:G940-G948.
83) Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van
Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Lancet 2015;385:956-965.
84) Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM,
Goodman Z, et al. Obeticholic acid for the treatment of
non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet
2019;394:2184-2196.
85) Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N,
Hoofnagle JH, et al. Clinical and metabolic effects associated with
weight changes and obeticholic acid in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2018;47:645-656.
86) Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R.
Bile acid reduces the secretion of very low density lipoprotein
by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem
2004;279:45685-45692.
87) Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M,
Garnys L, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol 2017;66:724-733.
88) Carino A, Cipriani S, Marchiano S, Biagioli M, Santorelli C,
Donini A, et al. BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis
and fibrosis. Sci Rep 2017;7:42801.
503